PLACE OF MAGNESIUM OROTATE IN THE COMPLEX THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH HYPERURICEMIA

Authors

  • Karachentsev Yu. I. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine; Kharkovskaya medical Academy of postgraduate education of the Ministry of health of Ukraine, Kharkiv, Ukraine
  • Kravchun N. A. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine; Kharkiv national medical University, Kharkiv, Ukraine
  • Chernyaeva A. A. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine; Kharkovskaya medical Academy of postgraduate education of the Ministry of health of Ukraine, Kharkiv, Ukraine
  • Dunaeva I. P. Kharkovskaya medical Academy of postgraduate education of the Ministry of health of Ukraine, Kharkiv, Ukraine
  • Kholodny A. V. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Efimenko T. I. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Ashurov E. M. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2020.1.03

Keywords:

type 2 diabetes mellitus, hyperuricemia, insulin resistance, uric acid, blood lipid spectrum, magnesium orotate.

Abstract

One of the actual problems of management of patients with type 2 diabetes in combination with HUE is the choice of optimal complex drug therapy. The aim of the study was to evaluate the effectiveness of magnesium orotate in combination with standard hypoglycemic therapy in patients with type 2 diabetes with HUE. 161 patients with type 2 diabetes were examined (67 men and 94 women) who received oral hypoglycemic therapy. The average age of men in the General group was (58.13 ± 10.13) [34–78] years, women — (61.33 ± 8.6) [42–81] years. The average duration of the disease in men (11.0 ± 8.15) years, in women — (12.35±8.94) years. HUE was diagnosed in 39.8 % (n = 64) of the examined patients. Patients with HUE along with standard hypoglycemic therapy were prescribed magnesium orotate: 1 week — 3 g per day, then 1.5 g per day for 3 months. Evaluation of the effectiveness of magnesium oroate therapy was carried out on the dynamics of the level of UA in the blood, glucose homeostasis, components of the blood lipid spectrum, heart rate and blood pressure. The data is analyzed using parametric statistics methods. It is shown that magnesium orotate therapy for 3 months in patients with type 2 diabetes with HUE, who receive oral hypoglycemic therapy, it contributes the level of UA in the blood, normalize the blood lipid spectrum and reduce the manifestations of insulin resistance; it leads to a decrease in heart rate and blood pressure, which significantly improves the clinical course of the disease and reduces the risk of developing chronic heart failure.

References

Keitel R, Keitel W. MMW Fortschr Med 2000; 142(12):48-50.

Dalbeth N, Wong S, Gamble GD, et al. Ann Rheumatic Dis 2010; 69(9): 1677-1682. doi: http://doi.org/10.1136/ard.2009.124230.

Rosenfeldt FL. Cardiovasc Drugs Ther 1998; 12(2): 147-152. doi:http://doi.org/10.1023/a:1007732131887.

Gaĭsin IR, Valeeva RM, Maksimov NI, et al. Kardiologiia 2013; 53(9): 33-39.

Ivanov DD, Dombrovskij JaA. Na dopomogu praktykujuchomu likarju 2014; 4(10): 55-58.

Trisvetova EL. Med Novosti 2017; 2: 68-72.

Barskova VG, Eliseev MS, Kudaeva FM, et al. Klin Medicina 2009; 7: 41-46.

Iljuhina OB, Madjanov IV. Prakt Medicina 2010; 43:122-124.

World Health Organization. Obesity: Preventing and managing the global epidemic. Technical report series no 894, Geneva, 2000: 23 р.

Global database on body mass index: BMI classification 2013, available at: http://apps.who.int/bmi/index.jsp?introPage =intro_3.html.

Klimov AN, Nikul’cheva JuG. Obmen lipidov i lipoproteidov i ih narushenija,Sankt-Peterburg, 1999: 505 p.

Chobanian A, Bakris G, Black H, et al. JAMA 2003;289(19): 2560-2572. doi: http://doi.org/10.1001/jama.289.19.2560.

Junkerov VI, Grigor’ev FG. Matematiko-statisticheskaja obrabotka dannyh medicinskih issledovanij, Sankt-Peterburg,

: 266 p.

Lakin GF. Biometrija: ucheb. posobie dlja biol. spec.Vuzov, Moskva, 1990: 352 p.

Givertz MM, Anstrom KJ, Redfield MM, et al. NHLBI Heart Failure Clin Res Network Circulation 2015;131(20): 1763-1771. doi: http://doi.org/10.1161/CIRCULATIONAHA.114.014536.

Chernjajeva AO, Mykytjuk MR, Karachencev JuI, Kravchun NO. Probl Endokryn Patologii’ 2019; 3: 73-80. doi:http://doi.org/10.21856/j-PEP.2019.2.11.

Downloads

Published

2021-07-05

How to Cite

Karachentsev, Y. I. ., Kravchun, N. A. ., Chernyaeva, A. A. ., Dunaeva, I. P. ., Kholodny, A. V. ., Efimenko, . T. I. ., & Ashurov, E. M. . (2021). PLACE OF MAGNESIUM OROTATE IN THE COMPLEX THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH HYPERURICEMIA. Problems of Endocrine Pathology, 71(1), 23-29. https://doi.org/10.21856/j-PEP.2020.1.03

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 3 4 > >>